SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00062803

Enrollment

Unknown

Registered

2003-06-17

Start date

2003-06-30

Completion date

2005-10-31

Last updated

2009-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Brief summary

Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes injections or infusions of an anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Assignment to either SR34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors.

Interventions

DRUGSR34006

DRUG(LMW)heparin

DRUGWarfarin VKA

DRUGAcenocoumarol VKA

Study design

Allocation

RANDOMIZED

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed acute symptomatic Pulmonary Embolism (PE) with or without concomitant Deep Vein Thrombosis (DVT) * Written informed consent

Exclusion criteria

* Legal lower age limitations (country specific) * Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of PE * Other indication for VKA than PE/DVT * More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW)heparin or initiation of VKA treatment prior to randomization * Participation in another pharmacotherapeutic study within the prior 30 days * Creatinine clearance \<10 mL/min, severe hepatic disease, or bacterial endocarditis * Life expectancy \<3 months * Active bleeding or high risk for bleeding * Uncontrolled hypertension: systolic blood pressure \>180 mm Hg or diastolic blood pressure \>110 mm Hg * Pregnancy or childbearing potential without proper contraceptive measures or women who are breastfeeding * Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin, enoxaparin, or tinzaparin

Design outcomes

Primary

Measure	Time frame
symptomatic recurrent pulmonary embolism or deep vein thrombosis within 3 months.	—

Secondary

Measure	Time frame
symptomatic recurrent PE/DVT within 6 months.	—

Countries

Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 6, 2026